Cargando…
Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study
Background: Treatment with mesenchymal stem cells (MSCs) has elicited considerable interest as an adjunctive therapy in sepsis. However, the encouraging effects of experiments with MSC in rodents have not been adequately studied in large-animal models with better relevance to human sepsis. Objective...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019005/ https://www.ncbi.nlm.nih.gov/pubmed/32117276 http://dx.doi.org/10.3389/fimmu.2020.00126 |
_version_ | 1783497431684481024 |
---|---|
author | Horak, Jan Nalos, Lukas Martinkova, Vendula Tegl, Vaclav Vistejnova, Lucie Kuncova, Jitka Kohoutova, Michaela Jarkovska, Dagmar Dolejsova, Martina Benes, Jan Stengl, Milan Matejovic, Martin |
author_facet | Horak, Jan Nalos, Lukas Martinkova, Vendula Tegl, Vaclav Vistejnova, Lucie Kuncova, Jitka Kohoutova, Michaela Jarkovska, Dagmar Dolejsova, Martina Benes, Jan Stengl, Milan Matejovic, Martin |
author_sort | Horak, Jan |
collection | PubMed |
description | Background: Treatment with mesenchymal stem cells (MSCs) has elicited considerable interest as an adjunctive therapy in sepsis. However, the encouraging effects of experiments with MSC in rodents have not been adequately studied in large-animal models with better relevance to human sepsis. Objectives: Here, we aimed to assess safety and efficacy of bone marrow-derived MSCs in a clinically relevant porcine model of progressive peritonitis-induced sepsis. Methods: Thirty-two anesthetized, mechanically ventilated, and instrumented pigs were randomly assigned into four groups (n = 8 per group): (1) sham-operated group (CONTROL); (2) sham-operated group treated with MSCs (MSC-CONTROL); (3) sepsis group with standard supportive care (SEPSIS); and (4) sepsis group treated with MSCs (MSC-SEPSIS). Peritoneal sepsis was induced by inoculating cultivated autologous feces. MSCs (1 × 10(6)/kg) were administered intravenously at 6 h after sepsis induction. Results: Before, 12, 18, and 24 h after the induction of peritonitis, we measured systemic, regional, and microvascular hemodynamics, multiple-organ functions, mitochondrial energy metabolism, systemic immune-inflammatory response, and oxidative stress. Administration of MSCs in the MSC-CONTROL group did not elicit any measurable acute effects. Treatment of septic animals with MSCs failed to mitigate sepsis-induced hemodynamic alterations or the gradual rise in Sepsis-related organ failure assessment scores. MSCs did not confer any protection against sepsis-mediated cellular myocardial depression and mitochondrial dysfunction. MSCs also failed to modulate the deregulated immune-inflammatory response. Conclusion: Intravenous administration of bone marrow-derived MSCs to healthy animals was well-tolerated. However, in this large-animal, clinically relevant peritonitis-induced sepsis model, MSCs were not capable of reversing any of the sepsis-induced disturbances in multiple biological, organ, and cellular systems. |
format | Online Article Text |
id | pubmed-7019005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70190052020-02-28 Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study Horak, Jan Nalos, Lukas Martinkova, Vendula Tegl, Vaclav Vistejnova, Lucie Kuncova, Jitka Kohoutova, Michaela Jarkovska, Dagmar Dolejsova, Martina Benes, Jan Stengl, Milan Matejovic, Martin Front Immunol Immunology Background: Treatment with mesenchymal stem cells (MSCs) has elicited considerable interest as an adjunctive therapy in sepsis. However, the encouraging effects of experiments with MSC in rodents have not been adequately studied in large-animal models with better relevance to human sepsis. Objectives: Here, we aimed to assess safety and efficacy of bone marrow-derived MSCs in a clinically relevant porcine model of progressive peritonitis-induced sepsis. Methods: Thirty-two anesthetized, mechanically ventilated, and instrumented pigs were randomly assigned into four groups (n = 8 per group): (1) sham-operated group (CONTROL); (2) sham-operated group treated with MSCs (MSC-CONTROL); (3) sepsis group with standard supportive care (SEPSIS); and (4) sepsis group treated with MSCs (MSC-SEPSIS). Peritoneal sepsis was induced by inoculating cultivated autologous feces. MSCs (1 × 10(6)/kg) were administered intravenously at 6 h after sepsis induction. Results: Before, 12, 18, and 24 h after the induction of peritonitis, we measured systemic, regional, and microvascular hemodynamics, multiple-organ functions, mitochondrial energy metabolism, systemic immune-inflammatory response, and oxidative stress. Administration of MSCs in the MSC-CONTROL group did not elicit any measurable acute effects. Treatment of septic animals with MSCs failed to mitigate sepsis-induced hemodynamic alterations or the gradual rise in Sepsis-related organ failure assessment scores. MSCs did not confer any protection against sepsis-mediated cellular myocardial depression and mitochondrial dysfunction. MSCs also failed to modulate the deregulated immune-inflammatory response. Conclusion: Intravenous administration of bone marrow-derived MSCs to healthy animals was well-tolerated. However, in this large-animal, clinically relevant peritonitis-induced sepsis model, MSCs were not capable of reversing any of the sepsis-induced disturbances in multiple biological, organ, and cellular systems. Frontiers Media S.A. 2020-02-07 /pmc/articles/PMC7019005/ /pubmed/32117276 http://dx.doi.org/10.3389/fimmu.2020.00126 Text en Copyright © 2020 Horak, Nalos, Martinkova, Tegl, Vistejnova, Kuncova, Kohoutova, Jarkovska, Dolejsova, Benes, Stengl and Matejovic. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Horak, Jan Nalos, Lukas Martinkova, Vendula Tegl, Vaclav Vistejnova, Lucie Kuncova, Jitka Kohoutova, Michaela Jarkovska, Dagmar Dolejsova, Martina Benes, Jan Stengl, Milan Matejovic, Martin Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study |
title | Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study |
title_full | Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study |
title_fullStr | Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study |
title_full_unstemmed | Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study |
title_short | Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study |
title_sort | evaluation of mesenchymal stem cell therapy for sepsis: a randomized controlled porcine study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019005/ https://www.ncbi.nlm.nih.gov/pubmed/32117276 http://dx.doi.org/10.3389/fimmu.2020.00126 |
work_keys_str_mv | AT horakjan evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT naloslukas evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT martinkovavendula evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT teglvaclav evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT vistejnovalucie evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT kuncovajitka evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT kohoutovamichaela evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT jarkovskadagmar evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT dolejsovamartina evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT benesjan evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT stenglmilan evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy AT matejovicmartin evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy |